Segmentation highlights:
Japanese Encephalitis Vaccines Market Type Outlook (Revenue, USD Million, 2021-2026)
- Inactivated vaccines - size and forecast 2021-2026
- Recombinant vaccines - size and forecast 2021-2026
- Live attenuated vaccines - size and forecast 2021-2026
The inactivated vaccines segment will generate maximum revenue in the market through the forecast period. The increasing number of choices and the availability of wide treatment options are increasing the popularity of inactivated vaccines. Also, the need for booster injections for inactivated vaccines is expected to help the segment grow in terms of both volume and value during the forecast period.
Japanese Encephalitis Vaccines Market Geography Outlook (Revenue, USD Million, 2021-2026)
- Asia - size and forecast 2021-2026
- Rest of World (ROW) - size and forecast 2021-2026
- Europe - size and forecast 2021-2026
- North America - size and forecast 2021-2026
72% of the overall market growth is expected to come from Asia. Over three billion people in the region are at the risk of the indication. As there is no cure for the disease, many global vendors such as Sanofi, Valneva, and Bharat Biotech, and organizations such as UNICEF, WHO, and Gavi are focusing on preventing the virus by introducing new vaccines. In addition, the Japanese encephalitis vaccine has been added to the national immunization plan of various Asian countries, including India and China, which are currently at the highest risk of coming into contact with the Japanese encephalitis virus.
Vendor Landscape:
The global Japanese encephalitis vaccines market is concentrated and is a highly regulated market with a limited number of vendors operating in the market. The rivalry between vendors is low due to the limited scope of commercialization available for the indication. The market is not expected to witness any major shift in the market structure during the forecast period. The following are identified as some of the major players in the global Japanese encephalitis vaccines market.
- Adimmune Corp.
- Bharat Biotech Ltd.
- Biological E. Ltd.
- KM Biologics Co. Ltd.
- Medigen Inc.
- Panacea Biotec Ltd.
- Sanofi
- Shandong Hengye Biotechnology Co. Ltd.
- Valneva SE
For more insights on the vendor landscape, View Our Free Sample Report.
Japanese Encephalitis Vaccines Market: Growth Drivers
The market is mainly driven by the inclusion of the approved vaccines in the national immunization plans in the endemic countries. Governments in the countries that face the maximum risk of Japanese encephalitis are introducing national immunization plans to vaccinate the population against the virus. For instance, in March 2020, the Ministery for Health and Aged Care in Australia announced its plans to support vaccination for Japanese encephalitis and COVID-19 with USD 2.1 billion in investments. Similarly, in September 2021, a vaccination campaign was conducted in Assam, India, where people in the age group of 15-65 years were vaccinated with the Japanese encephalitis vaccine. Such immunization plans are expected to drive the growth of the global Japanese encephalitis vaccines market during the forecast period.
Read Our Free Sample to identify other factors impacting the market growth.
Related Reports:
Influenza Vaccine Market by Type and Geography - Forecast and Analysis 2022-2026
Hepatitis B Therapeutics Market by Application and Geography - Forecast and Analysis 2022-2026
Japanese Encephalitis Vaccines Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.98% |
Market growth 2022-2026 |
USD 58.27 million |
Market structure |
Concentrated |
YoY growth (%) |
5.38 |
Regional analysis |
Asia, Rest of World (ROW), Europe, and North America |
Performing market contribution |
Asia at 72% |
Key consumer countries |
Australia, China, India, Japan, and Republic of Korea |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Adimmune Corp., Bharat Biotech Ltd., Biological E. Ltd., KM Biologics Co. Ltd., Medigen Inc., Panacea Biotec Ltd., Sanofi, Shandong Hengye Biotechnology Co. Ltd., and Valneva SE |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- Exhibit 02: Market characteristics
- 2.2 Value chain analysis
- Exhibit 03: Value chain analysis: Pharmaceutical market
3 Market Sizing
- 3.1 Market definition
- Exhibit 04: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 05: Market segments
- 3.4 Market outlook: Forecast for 2020 - 2025
- Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
- Exhibit 07: Approved vaccines for Japanese encephalitis
- Exhibit 08: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 09: Five forces analysis 2020 & 2025
- 4.2 Bargaining power of buyers
- Exhibit 10: Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- Exhibit 11: Bargaining power of suppliers
- 4.4 Threat of new entrants
- Exhibit 12: Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 13: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 14: Threat of rivalry
- 4.7 Market condition
- Exhibit 15: Market condition - Five forces 2020
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 16: Type - Market share 2020-2025 (%)
- 5.2 Comparison by Type
- Exhibit 17: Comparison by Type
- 5.3 Inactivated vaccines - Market size and forecast 2020-2025
- Exhibit 18: Inactivated vaccines - Market size and forecast 2020-2025 ($ million)
- Exhibit 19: Inactivated vaccines - Year-over-year growth 2020-2025 (%)
- 5.4 Recombinant vaccines - Market size and forecast 2020-2025
- Exhibit 20: Recombinant vaccines - Market size and forecast 2020-2025 ($ million)
- Exhibit 21: Recombinant vaccines - Year-over-year growth 2020-2025 (%)
- 5.5 Live attenuated vaccines - Market size and forecast 2020-2025
- Exhibit 22: Live attenuated vaccines - Market size and forecast 2020-2025 ($ million)
- Exhibit 23: Live attenuated vaccines - Year-over-year growth 2020-2025 (%)
- 5.6 Market opportunity by Type
- Exhibit 24: Market opportunity by Type
6 Customer landscape
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 26: Market share by geography 2020-2025 (%)
- 7.2 Geographic comparison
- Exhibit 27: Geographic comparison
- 7.3 Asia - Market size and forecast 2020-2025
- Exhibit 28: Asia - Market size and forecast 2020-2025 ($ million)
- Exhibit 29: Asia - Year-over-year growth 2020-2025 (%)
- 7.4 ROW - Market size and forecast 2020-2025
- Exhibit 30: ROW - Market size and forecast 2020-2025 ($ million)
- Exhibit 31: ROW - Year-over-year growth 2020-2025 (%)
- 7.5 Europe - Market size and forecast 2020-2025
- Exhibit 32: Europe - Market size and forecast 2020-2025 ($ million)
- Exhibit 33: Europe - Year-over-year growth 2020-2025 (%)
- 7.6 North America - Market size and forecast 2020-2025
- Exhibit 34: North America - Market size and forecast 2020-2025 ($ million)
- Exhibit 35: North America - Year-over-year growth 2020-2025 (%)
- 7.7 Key leading countries
- Exhibit 36: Key leading countries
- 7.8 Market opportunity by geography
- Exhibit 37: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.2 Market challenges
- Exhibit 38: Impact of drivers and challenges
9 Vendor Landscape
- 9.1 Overview
- Exhibit 39: Vendor landscape
- 9.2 Landscape disruption
- Exhibit 40: Landscape disruption
- Exhibit 41: Industry risks
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 42: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 43: Market positioning of vendors
- 10.3 Adimmune Corp.
- Exhibit 44: Adimmune Corp. - Overview
- Exhibit 45: Adimmune Corp. - Business segments
- Exhibit 46:Adimmune Corp. - Key news
- Exhibit 47: Adimmune Corp. - Key offerings
- 10.4 Bharat Biotech Ltd.
- Exhibit 48: Bharat Biotech Ltd. - Overview
- Exhibit 49: Bharat Biotech Ltd. - Product and service
- Exhibit 50:Bharat Biotech Ltd. - Key news
- Exhibit 51: Bharat Biotech Ltd. - Key offerings
- 10.6 KM Biologics Co. Ltd.
- Exhibit 56: KM Biologics Co. Ltd. - Overview
- Exhibit 57: KM Biologics Co. Ltd. - Product and service
- Exhibit 58: KM Biologics Co. Ltd. - Key offerings
- 10.7 Medigen Inc.
- Exhibit 59: Medigen Inc. - Overview
- Exhibit 60: Medigen Inc. - Product and service
- Exhibit 61: Medigen Inc. - Key offerings
- 10.8 Panacea Biotec Ltd
- Exhibit 62: Panacea Biotec Ltd - Overview
- Exhibit 63: Panacea Biotec Ltd - Business segments
- Exhibit 64:Panacea Biotec Ltd. - Key news
- Exhibit 65: Panacea Biotec Ltd - Key offerings
- Exhibit 66: Panacea Biotec Ltd - Segment focus
- 10.9 Sanofi
- Exhibit 67: Sanofi - Overview
- Exhibit 68: Sanofi - Business segments
- Exhibit 69:Sanofi - Key news
- Exhibit 70: Sanofi - Key offerings
- Exhibit 71: Sanofi - Segment focus
- 10.10 Shandong Hengye Biotechnology Co. Ltd.
- Exhibit 72: Shandong Hengye Biotechnology Co. Ltd. - Overview
- Exhibit 73: Shandong Hengye Biotechnology Co. Ltd. - Product and service
- Exhibit 74: Shandong Hengye Biotechnology Co. Ltd. - Key offerings
- 10.11 VA Bio+Tech Park
- Exhibit 75: VA Bio+Tech Park - Overview
- Exhibit 76: VA Bio+Tech Park - Product and service
- Exhibit 77: VA Bio+Tech Park - Key offerings
- 10.12 Valneva SE
- Exhibit 78: Valneva SE - Overview
- Exhibit 79: Valneva SE - Business segments
- Exhibit 80:Valneva SE - Key news
- Exhibit 81: Valneva SE - Key offerings
- Exhibit 82: Valneva SE - Segment focus
11 Appendix
- 11.2 Currency conversion rates for US$
- Exhibit 83: Currency conversion rates for US$
- 11.3 Research methodology
- Exhibit 84: Research Methodology
- Exhibit 85: Validation techniques employed for market sizing
- Exhibit 86: Information sources
- 11.4 List of abbreviations
- Exhibit 87: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article